Fundamental Analysis of CERVOMED INC(NASDAQ:CRVO) stock

Fundamental Rating

We assign a fundamental rating of 3 out of 10 to CRVO. CRVO was compared to 573 industry peers in the Biotechnology industry. While CRVO has a great health rating, there are worries on its profitability. While showing a medium growth rate, CRVO is valued expensive at the moment.

Quickly go to:

1. Profitability

1.1 Basic Checks

In the past year CRVO has reported negative net income.

CRVO had a negative operating cash flow in the past year.

In the past 5 years CRVO always reported negative net income.

In the past 5 years CRVO always reported negative operating cash flow.

1.2 Ratios

CRVO has a Return On Assets (-50.58%) which is in line with its industry peers.

Looking at the Return On Equity, with a value of -68.37%, CRVO is in line with its industry, outperforming 57.22% of the companies in the same industry.

		Industry Rank	Sector Rank
ROA	-50.58%
ROE	-68.37%
ROIC	N/A

ROA(3y)-51.44%

ROA(5y)-52.29%

ROE(3y)-58.53%

ROE(5y)-59.85%

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

CRVO does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	N/A
GM	N/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

Compared to 1 year ago, CRVO has more shares outstanding

CRVO has more shares outstanding than it did 5 years ago.

CRVO has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.

2.2 Solvency

CRVO has an Altman-Z score of 24.31. This indicates that CRVO is financially healthy and has little risk of bankruptcy at the moment.

CRVO has a Altman-Z score of 24.31. This is amongst the best in the industry. CRVO outperforms 94.01% of its industry peers.

CRVO has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.

		Industry Rank	Sector Rank
Debt/Equity	0
Debt/FCF	N/A
Altman-Z	24.31

ROIC/WACCN/A

WACCN/A

2.3 Liquidity

CRVO has a Current Ratio of 3.84. This indicates that CRVO is financially healthy and has no problem in meeting its short term obligations.

CRVO has a Current ratio (3.84) which is in line with its industry peers.

A Quick Ratio of 3.84 indicates that CRVO has no problem at all paying its short term obligations.

The Quick ratio of CRVO (3.84) is comparable to the rest of the industry.

		Industry Rank	Sector Rank
Current Ratio	3.84
Quick Ratio	3.84

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

CRVO shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 93.55%, which is quite impressive.

The Revenue has grown by 208.52% in the past year. This is a very strong growth!

EPS 1Y (TTM)93.55%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%-142.94%

Revenue 1Y (TTM)208.52%

Revenue growth 3YN/A

Revenue growth 5YN/A

Sales Q2Q%5.08%

3.2 Future

CRVO is expected to show a very negative growth in Earnings Per Share. In the coming years, the EPS will decrease by -53.75% yearly.

The Revenue is expected to grow by 39.93% on average over the next years. This is a very strong growth

EPS Next Y-20.99%

EPS Next 2Y-48.16%

EPS Next 3Y-44.97%

EPS Next 5Y-53.75%

Revenue Next Year53.73%

Revenue Next 2Y-14.77%

Revenue Next 3Y-25.99%

Revenue Next 5Y39.93%

3.3 Evolution

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

CRVO reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.

Also next year CRVO is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A

4.2 Price Multiples

		Industry Rank	Sector Rank
P/FCF	N/A
EV/EBITDA	N/A

4.3 Compensation for Growth

CRVO's earnings are expected to decrease with -44.97% in the coming years. This may justify a cheaper valuation.

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2Y-48.16%

EPS Next 3Y-44.97%

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

CRVO does not give a dividend.

		Industry Rank	Sector Rank
Dividend Yield	N/A

More info and screens

Find the best dividend stocks

Show peers with best dividend

CERVOMED INC

NASDAQ:CRVO (9/16/2024, 3:12:06 PM)

16.58

-0.93 (-5.31%)

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences

GICS IndustryBiotechnology

Earnings (Last)

Earnings (Next)

Inst Owners

Inst Owner Change

Ins Owners

Ins Owner Change

Market Cap136.78M

Analysts

Price Target

Dividend

		Industry Rank	Sector Rank
Dividend Yield	N/A

Dividend Growth(5Y)

Div Incr Years

Div Non Decr Years

Ex-Date

Surprises & Revisions

EPS beat(2)

Avg EPS beat(2)

Min EPS beat(2)

Max EPS beat(2)

EPS beat(4)

Avg EPS beat(4)

Min EPS beat(4)

Max EPS beat(4)

EPS beat(8)

Avg EPS beat(8)

EPS beat(12)

Avg EPS beat(12)

EPS beat(16)

Avg EPS beat(16)

Revenue beat(2)

Avg Revenue beat(2)

Min Revenue beat(2)

Max Revenue beat(2)

Revenue beat(4)

Avg Revenue beat(4)

Min Revenue beat(4)

Max Revenue beat(4)

Revenue beat(8)

Avg Revenue beat(8)

Revenue beat(12)

Avg Revenue beat(12)

Revenue beat(16)

Avg Revenue beat(16)

PT rev (1m)

PT rev (3m)

EPS NQ rev (1m)

EPS NQ rev (3m)

EPS NY rev (1m)

EPS NY rev (3m)

Revenue NQ rev (1m)

Revenue NQ rev (3m)

Revenue NY rev (1m)

Revenue NY rev (3m)

Valuation

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A
P/S
P/FCF
P/OCF
P/B
P/tB
EV/EBITDA

EPS(TTM)

EPS(NY)

Fwd EY

FCF(TTM)

FCFY

OCF(TTM)

OCFY

SpS

BVpS

TBVpS

PEG (NY)N/A

PEG (5Y)N/A

Profitability

		Industry Rank	Sector Rank
ROA	-50.58%
ROE	-68.37%
ROCE
ROIC
ROICexc
ROICexgc
OM	N/A
PM (TTM)	N/A
GM	N/A
FCFM

ROA(3y)

ROA(5y)

ROE(3y)

ROE(5y)

ROIC(3y)

ROIC(5y)

ROICexc(3y)

ROICexc(5y)

ROICexgc(3y)

ROICexgc(5y)

ROCE(3y)

ROCE(5y)

ROICexcg growth 3Y

ROICexcg growth 5Y

ROICexc growth 3Y

ROICexc growth 5Y

OM growth 3Y

OM growth 5Y

PM growth 3Y

PM growth 5Y

GM growth 3Y

GM growth 5Y

F-Score

Asset Turnover0.97

Health

		Industry Rank	Sector Rank
Debt/Equity	0
Debt/FCF
Debt/EBITDA
Cap/Depr
Cap/Sales
Interest Coverage
Cash Conversion
Profit Quality
Current Ratio	3.84
Quick Ratio	3.84
Altman-Z

F-Score

WACC

ROIC/WACC

Cap/Depr(3y)

Cap/Depr(5y)

Cap/Sales(3y)

Cap/Sales(5y)

Profit Quality(3y)

Profit Quality(5y)

High Growth Momentum

Growth

EPS 1Y (TTM)93.55%

EPS 3YN/A

EPS 5Y

EPS Q2Q%

EPS Next Y-20.99%

EPS Next 2Y

EPS Next 3Y

EPS Next 5Y

Revenue 1Y (TTM)208.52%

Revenue growth 3YN/A

Revenue growth 5Y

Sales Q2Q%

Revenue Next Year

Revenue Next 2Y

Revenue Next 3Y

Revenue Next 5Y

EBIT growth 1Y

EBIT growth 3Y

EBIT growth 5Y

EBIT Next Year

EBIT Next 3Y

EBIT Next 5Y

FCF growth 1Y

FCF growth 3Y

FCF growth 5Y

OCF growth 1Y

OCF growth 3Y

OCF growth 5Y

CERVOMED INC (CRVO)

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens